Roquefort Therapeutics plc (ROQ)
Market Closed
2 Jun, 15:30
LSE LSE Primary 11. 75
GBX 0
0%
155.54K Market Cap
- P/E Ratio
- Div Yield
83,638 Volume
- Eps
11.75 GBX
Previous Close Want to track ROQ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ROQ closed yesterday higher at 11.75 GBX, an increase of 0% from Monday's close, completing a monthly increase of 56.67% or 4.25 GBX. Over the past 12 months, ROQ stock gained 840%.
ROQ is not paying dividends to its shareholders.
The last earnings report, released on Apr 28, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Roquefort Therapeutics plc has completed 1 stock splits, with the recent split occurring on Mar 27, 2026.
The company's stock is traded on one exchange.
Roquefort Therapeutics plc (ROQ) FAQ
What is the stock price today?
The current price is 11.75 GBX.
On which exchange is it traded?
Roquefort Therapeutics plc is listed on LSE.
What is its stock symbol?
The ticker symbol is ROQ.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 155.54K.
Has Roquefort Therapeutics plc ever had a stock split?
Roquefort Therapeutics plc had 1 splits and the recent split was on Mar 27, 2026.
Roquefort Therapeutics plc Profile
| Biotechnology Industry | Healthcare Sector | Dr. Darrin Matthew Disley O.B.E., Ph.D. CEO | LSE Exchange | GB00BMDQ2T15 ISIN |
| US Country | 7 Employees | - Last Dividend | 27 Mar 2026 Last Split | - IPO Date |
Overview
Roquefort Therapeutics plc is a biotechnology firm focused on the innovation of novel cancer treatments. Incorporated in 2020 and situated in London, the United Kingdom, the company specializes in the discovery and development of therapeutic solutions that target various aspects of cancer biology. Leveraging a deep understanding of oncology and cutting-edge biotechnological methodologies, Roquefort Therapeutics strives to advance the field of cancer treatment through its diverse pre-clinical pipeline.
Products and Services
- Midkine Antibodies: Developed as part of its pre-clinical development pipeline, these antibodies have shown significant efficacy and promising results in toxicology studies. The focus on Midkine, a growth factor implicated in the progression of various cancers, targets its role in tumor growth and metastasis, offering a potential therapeutic option for cancer patients.
- Midkine RNA Therapeutics: Encompassing novel anti-cancer gene editing actions, Roquefort Therapeutics' RNA-based treatment options aim to modulate the expression of Midkine at the genetic level. This approach represents a cutting-edge direction in cancer therapy by altering the disease's pathway at its root cause.
- Midkine mRNA Therapeutics: These therapeutics use messenger RNA (mRNA) to stimulate a novel anti-cancer approach, targeting the synthesis of proteins vital for cancer cell growth and survival. By manipulating mRNA, Roquefort Therapeutics seeks to disrupt the production of key proteins that facilitate cancer progression.
- STAT-6 siRNA Therapeutics: Focused on targeting solid tumors, these small interfering RNA (siRNA) therapeutics aim to silence the STAT-6 gene, which plays a significant role in cancer cell proliferation and survival. The demonstration of significant in vivo efficacy highlights the potential of STAT-6 siRNA in treating various solid tumor indications.
- MK Cell Therapy: This novel cell therapy employs multiple mechanisms, including direct and natural killer (NK)-mediated actions, to target and destroy cancer cells. By harnessing the innate power of the immune system, MK cell therapy represents a promising avenue for the treatment of cancers through immunotherapeutic strategies.
Contact Information
Address: 55 Philo Blvd, Edison, NJ, United States, 08837
Phone: 44 20 3918 8633
Website: https://www.roquefortplc.com
